Date: 2011-03-23
Type of information: Licensing agreement
Compound: Debio 1142
Company: Debiopharm (Switzerland) Aurigene (India)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
development
commercialisation
Action mechanism: novel inhibitor of an undisclosed oncology pathway
Disease:
Details: Debiopharm , a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Aurigene Discovery Technologies Ltd have signed an option and exclusive worldwide license agreement concerning the development and commercialisation of Debio 1142, a novel inhibitor of an undisclosed oncology pathway.
Financial terms:
Latest news:
